Recommendations of the heparin-induced thrombocytopenia (HIT) Working Group found that systemwide improvements in the management of HIT are necessary to improve patient care. The group's main goals were to identify the most prominent gaps in HIT awareness to help enhance diagnosis and treatment to facilitate changes in HIT management that may result in favorable patient outcomes. A significant finding was that HIT is not recognized in many institutions.
"Physicians and other health care providers must regard HIT as a limb-and-life-threatening condition and approach care of the HIT patient with appropriate urgency,"said HIT Working Group moderator Larry Rice, MD. "We need a focused effort to increase physician awareness and facilitate the widespread adoption of aggressive HIT treatment strategies."
The Group's recommendations include:
The HIT Working Group is a consortium of 20 experts in anticoagulation medicine who recently held a series of meetings to discuss HIT management. GlaxoSmithKline sponsored the initiative.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs